By Dr Adam Jacob Bryant

Journal articles

Bryant A; Quach H, 2024, 'Biomarker-directed therapy in multiple myeloma', Current Opinion in Oncology, 36, pp. 600 - 609, http://dx.doi.org/10.1097/CCO.0000000000001091

Li EW; Jones E; Bryant C; King T; Talaulikar D; Ng JY; Bryant A; Ridha Z; Doo NW; Menzies A; Ling S; Ho SJ; Abadir E; Vanguru V; Joshua D; Ho PJ, 2024, 'A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies', European Journal of Haematology, 113, pp. 521 - 529, http://dx.doi.org/10.1111/ejh.14266

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Ribas de Almeida AC; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Pitombeira de Lacerda M; Martinez GA; Balarí AMS; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah AO; Oriol A; Gatt ME; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; McKeown A; McNamara S; Zhou X; Nichols M; Lewis E; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos MV, 2024, 'Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma', New England Journal of Medicine, 391, pp. 393 - 407, http://dx.doi.org/10.1056/NEJMoa2405090

Tong MH; Kwok A; Walsh A; Heydon P; Koh ES; McNamara N; Bryant A, 2024, 'Isolated Ocular Relapse of Acute Myeloid Leukaemia Post Allogeneic Stem Cell Transplant', Case Reports in Ophthalmological Medicine, 2024, pp. 2235819, http://dx.doi.org/10.1155/2024/2235819

Al‐Ammari M; Hsu D; Bryant A, 2024, 'Myeloma‐associated hemophagocytic lymphohistiocytosis – A comprehensive case study and a novel chemotherapy‐free approach with anakinra', eJHaem, 5, pp. 1057 - 1062, http://dx.doi.org/10.1002/jha2.975

Ponraj R; Bryant A; Dunlop L; Range H; Cobrador C; Ling S; Hsu D, 2023, 'Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA', Blood Cancer Journal, 13, pp. 113, http://dx.doi.org/10.1038/s41408-023-00885-9

Plesner T; Harrison SJ; Quach H; Lee C; Bryant A; Vangsted A; Estell J; Delforge M; Offner F; Twomey P; Choeurng V; Li J; Hendricks R; Ruppert SM; Sumiyoshi T; Miller K; Cho E; Schjesvold F, 2023, 'Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma', Clinical Hematology International, 5, pp. 43 - 51, http://dx.doi.org/10.1007/s44228-022-00023-5

McCaughan GJ; Verma A; Ling S; Lavee O; Moore JJ; Bryant A, 2021, 'Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres', Bone Marrow Transplantation, 56, pp. 738 - 740, http://dx.doi.org/10.1038/s41409-020-01086-9

Othman J; Greenwood M; Moore J; Larsen S; Watson AM; Arthur C; Bhattacharyya A; Bilmon I; Blyth E; Bryant A; Bryant C; Dunlop L; Fay K; Gibson J; Hamad N; Kerridge I; Kwan J; Ma D; Micklethwaite K; Milliken S; Panicker S; Stevenson W; Withers B; Wilcox L; Tran S; Gottlieb DJ, 2020, 'Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG', Biology of Blood and Marrow Transplantation, 26, pp. 1868 - 1875, http://dx.doi.org/10.1016/j.bbmt.2020.06.030

Palma CA; Al Sheikha D; Lim TK; Bryant A; Vu TT; Jayaswal V; Ma DDF, 2014, 'MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia', Molecular Cancer, 13, http://dx.doi.org/10.1186/1476-4598-13-79

Dalal BI; Al Mugairi A; Pi S; Lee SY; Khare NS; Pal J; Bryant A; Vakil AP; Lau S; Abou Mourad YR, 2014, 'Aberrant expression of CD13 identifies a subgroup of standard-risk adult acute lymphoblastic leukemia with inferior survival.', Clin Lymphoma Myeloma Leuk, 14, pp. 239 - 244, http://dx.doi.org/10.1016/j.clml.2013.10.003

Bryant A; Nivison-Smith I; Pillai ES; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil S; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearing R; Moore J, 2014, 'Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients', Bone Marrow Transplantation, 49, pp. 17 - 23, http://dx.doi.org/10.1038/bmt.2013.142

Bilmon I; Nivison-Smith I; Hertzberg M; Ritchie D; Greenwood M; Spencer A; Kennedy G; Bryant A; Moore J, 2014, 'Outcomes following second allogeneic haematopoietic transplants using fludarabine–melphalan conditioning', Bone Marrow Transplantation, 49, pp. 852 - 853, http://dx.doi.org/10.1038/bmt.2014.23

Bryant A; Palma CA; Jayaswal V; Yang YH; Lutherborrow MA; Ma DD, 2012, 'miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death', Molecular Cancer, 11, pp. 8, http://dx.doi.org/10.1186/1476-4598-11-8

Loi TH; Campain A; Bryant AJ; Molloy T; Lutherborrow MA; Turner J; Yang YH; Ma DD, 2011, 'Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling', BMC Medical Genomics, 4, pp. 1 - 10, http://www.biomedcentral.com/1755-8794/4/27

Lutherborrow MA; Bryant AJ; Jayaswal V; Agapiou DJ; Palma CA; Yang YH; Ma DD, 2011, 'Expression profiling of cytogenetically normal acute myeloid leukemia identifies MicroRNAs that target genes involved in monocytic differentiation', American Journal of Hematology, 86, pp. 2 - 11, http://dx.doi.org/10.1002/ajh.21864

Sasson SC; Smith S; Seddiki N; Zaunders J; Bryant AJ; Koelsch KK; Weatherall CJ; Munier CM; McGinley C; Yeung J; Mulligan S; Moore JJ; Cooper DA; Milliken ST; Kelleher AD, 2010, 'IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers', Cytokine, 50, pp. 58 - 68

Bryant A; Lutherborrow MA; Ma DD, 2009, 'The clinicopathological relevance of microRNA in normal and malignant haematopoiesis', Pathology, 41, pp. 204 - 213

Bryant A; Milliken ST, 2008, 'Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma', Biology of Blood and Marrow Transplantation, 14, pp. 601 - 602, http://dx.doi.org/10.1016/j.bbmt.2008.01.010

Bryant A; Low J; Austin SA; Joseph JE, 2008, 'Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T`s score and particle gel immunoassay', British Journal of Haematology, 143, pp. 721 - 726

Bryant A; Moore J, 2006, 'Rituximab and its potential for the treatment of rheumatoid arthritis', Therapeutics and Clinical Risk Management, 2, pp. 207 - 212, http://dx.doi.org/10.2147/tcrm.2006.2.2.207

Back to profile page